Compare DexCom, Inc. (DXCM) vs Moody's Corporation (MCO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Moody's Corporation — how do they compare? DexCom, Inc. trades at $72.58 (market cap $28.06B), while Moody's Corporation trades at $517.67 (market cap $88.12B). The key difference: Moody's Corporation is far larger — about 3.1× DexCom, Inc.'s market cap, and Moody's Corporation pays a 0.82% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals.
| DXCM | MCO | |
|---|---|---|
Market Cap | $28.06B | $88.12B |
Sector | Health | Financials |
52-Week High | $89.53 | $539.61 |
52-Week Low | $54.84 | $412.23 |
Enterprise Value | $27.03B | $93.92B |
Dividend Yield | — | 0.82% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $77.31, up 4.3% on the day, with a bullish technical outlook as it approaches resistance near $78. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.56 surpassing expectations of $0.47. Revenue growth accelerated to $4.66 billion in 2025, while net income margin expanded to 17.93%. Recent regulatory approvals, including Health Canada authorization for the G7 15-day CGM, support continued international expansion.
The stock offers growth potential with analyst consensus price target of $84.33, though high valuation multiples (P/E 31.21) and competition in the CGM market present risks. Expansion into non-insulin Type 2 diabetes and pediatric markets could drive future revenue, but commercial uptake remains unproven. Institutional sentiment remains strongly bullish with 80% buy ratings.
MCO trades at $515, up 4.1% today, near its 52-week high. The stock shows strong technical momentum with bullish moving averages and support at $501. Fundamentally, Moody's delivered three consecutive earnings beats with Q1 2026 EPS of $4.33 beating expectations. Revenue grew to $7.72B in 2025 with exceptional profitability margins (net margin 31.69%, ROE 74.54%). Recent developments include AI integration initiatives and a $1.03 dividend payment scheduled for June 2026.
Outlook remains positive with analyst consensus target at $539.40 (4.7% upside) and 56% buy ratings. Key opportunities include AI-driven growth and sustained debt issuance demand. Risks include high valuation multiples (P/E 36.19) and sensitivity to credit cycle changes. Cash flow trends show volatility with 2026 projection of -$670M net cash flow requiring monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Moody's Corporation
Moody's, along with S&P Ratings, is a leading provider of credit ratings on fixed income securities. Moody's ratings segment, known as Moody's Investors Service or MIS, includes corporates, structured finance, financial institutions, and public finance ratings. MIS represents a majority of the firm's revenue and profits. Moody's other segment is Moody's Analytics and consists of Research, Data, and Analytics or RD&A and Enterprise Risk Solutions or ERS. RD&A's products include credit research, quantitative credit scores, economic research, business intelligence, know your customer (KYC) tools, commercial real estate data and analytical tools, and training services. ERS includes risk management software solutions to financial institutions.
Read more on MCO →
